NEW YORK CITY, NY / ACCESS Newswire / November 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc ("Waldencast" or the "Company") (NASDAQ:WALD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Waldencast and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On November 24, 2025, Waldencast issued a press release reporting its financial results for the second quarter of 2025. Therein, the Company updated its financial outlook for the full year of 2025, expecting net revenue to be broadly in line with 2024 and adjusted EBITDA margin in the high single digits. Previously, Waldencast had guided to mid-teens net revenue growth and an adjusted EBITDA margin in the mid-to-high teens. The Company also reported a net loss of $185.2 million for the first half of 2025, primarily driven by impairment charges of $132.1 million and $20 million on its Obagi Medical and Milk Makeup brands, respectively.
On this news, Waldencast’s Class A ordinary share price fell $0.20 per share, or 6.49%, to close at $2.88 per share on November 24, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Pomerantz LLP
View the original press release on ACCESS Newswire
COMTEX_470566942/2457/2025-11-26T11:47:26